Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
You may also be interested in...
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.